PFE vs. JNJ, ABBV, MRK, BMY, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPN
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Pfizer vs.
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Johnson & Johnson has a net margin of 18.20% compared to Pfizer's net margin of 12.62%. Johnson & Johnson's return on equity of 34.24% beat Pfizer's return on equity.
Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.0%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.9%. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Pfizer pays out 122.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has raised its dividend for 63 consecutive years and Pfizer has raised its dividend for 16 consecutive years.
Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Johnson & Johnson presently has a consensus price target of $171.33, suggesting a potential upside of 4.97%. Pfizer has a consensus price target of $31.92, suggesting a potential upside of 27.43%. Given Pfizer's stronger consensus rating and higher possible upside, analysts clearly believe Pfizer is more favorable than Johnson & Johnson.
In the previous week, Johnson & Johnson had 14 more articles in the media than Pfizer. MarketBeat recorded 107 mentions for Johnson & Johnson and 93 mentions for Pfizer. Johnson & Johnson's average media sentiment score of 1.25 beat Pfizer's score of 1.02 indicating that Johnson & Johnson is being referred to more favorably in the media.
Pfizer received 389 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.03% of users gave Pfizer an outperform vote while only 64.93% of users gave Johnson & Johnson an outperform vote.
Summary
Johnson & Johnson beats Pfizer on 15 of the 22 factors compared between the two stocks.
Get Pfizer News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:PFE) was last updated on 3/28/2025 by MarketBeat.com Staff
